The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).
 
Tian Zhang
Leadership - Capio BioSciences (I)
Stock and Other Ownership Interests - Capio Biosciences (I)
Honoraria - Exelixis; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Foundation Medicine; Genentech/Roche; Janssen; Pfizer; Pharmacyclics; Sanofi
Speakers' Bureau - Exelixis; Genentech/Roche; Genomic Health; Genzyme
Research Funding - Acerta Pharma (Inst); Janssen (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); OmniSeq (Inst); Personal Genome Diagnostics (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Acerta Pharma
 
Karla V. Ballman
Consulting or Advisory Role - ARIAD; Medtronic; Takeda
Patents, Royalties, Other Intellectual Property - Immune enrichment signature for response to trastuzumab in HER2+ breast cancer (Inst); Prostate cancer signature patent (Inst)
Expert Testimony - Janssen Oncology; Janssen Oncology; Lilly
 
Atish Dipankar Choudhury
Employment - LeMaitre Vascular (I)
Honoraria - Astellas Pharma; Bayer; Janssen
Research Funding - Bayer; Janssen (Inst)
Travel, Accommodations, Expenses - Genentech
 
Ronald C. Chen
Consulting or Advisory Role - Accuray; Bayer; Blue Earth Diagnostics; Medivation/Astellas
Research Funding - Accuray
 
Colleen Watt
No Relationships to Disclose
 
Yujia Wen
No Relationships to Disclose
 
Tyler Zemla
No Relationships to Disclose
 
Hamid Emamekhoo
Consulting or Advisory Role - Bayer; Exelixis
 
Shilpa Gupta
Stock and Other Ownership Interests - Nektar
Honoraria - Janssen Oncology
Consulting or Advisory Role - Exelixis; Genentech; Janssen Oncology; Merck; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Janssen Oncology
Research Funding - Astellas Medivation (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
 
Michael J. Morris
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; Bayer; Blue Earth Diagnostics; Endocyte; Tokai Pharmaceuticals; Tolmar
Speakers' Bureau - ORIC Pharmaceuticals
Research Funding - Bayer (Inst); Corcept Therapeutics (Inst); Endocyte (Inst); Progenics (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bayer; Endocyte
 
Daniel J. George
Leadership - Capio BioSciences
Honoraria - Acceleron Pharma; American Association for Cancer Research; Axess Oncology; Bayer; EMD Serono; Exelixis; Janssen Oncology; Millennium Medical Publishing; OncLive; Pfizer; Sanofi; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Innocrin Pharma; Janssen; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Sanofi
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Dendreon (Inst); Exelixis (Inst); Innocrin Pharma (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi
 
Toni K. Choueiri
Employment - Dana Farber Cancer Hospital
Leadership - Dana Farber Cancer Hospital; Kidney Cancer Association; NCCN
Honoraria - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Analysis Group (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel